Clinical trial
Correction of Psoriatic T Cell Signatures by Deucravacitinib
NCT05858645 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Correction of Psoriatic T Cell Signatures by Deucravacitinib
- Lead sponsor
- University of California, San Francisco
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- October 1, 2023
- Completion date
- June 30, 2028
- Enrollment
- 25 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
psoriasis vulgaris